ScreenerHero

LPCNLipocine Inc.

NAS · US · Healthcare · Biotechnology · lipocine.com
2.090USD+1.95%Mkt Cap: 17.23M $P/E: —

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone repl…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap17.23M $
Enterprise Value-5.78M $
Revenue (TTM)1.57M $
Gross Profit-6.61M $
Net Income (TTM)-9.63M $
Revenue/Share0.2400 USD
Last Price2.090 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees14
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.69
PEG—
EV/EBITDA0.46
EV/Revenue-3.68
P/S10.98
P/B0.79
EPS (TTM)-1.88
EPS (Forward)-1.24
52W Range
1.8103% of range12.37
52W High12.37 USD
52W Low1.810 USD
Profitability
Gross Margin-334.26%
Oper. Margin-1495.14%
EBITDA Margin0.00%
Profit Margin-487.06%
ROE-66.50%
ROA-56.61%
Growth
Revenue Growth-69.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-9.76M $
CapEx (TTM)—
FCF Margin-442.18%
FCF Yield-40.28%
Net Debt-23.01M $
Net Debt/EBITDA1.84
Balance Sheet
Debt/Equity1.18
Current Ratio11.48
Quick Ratio11.39
Book Value/Sh2.640 USD
Cash/Share2.822 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:17
Split DateMay 12, 2023
Analyst Consensus
Rating—
Target (Mean)6.000 USD
Upside (mean)+187.1%
Target Range6.000 USD – 6.000 USD
# Analysts1
Ownership
Shares Out.8.24M
Float6.55M
Insiders4.51%
Institutions36.19%
Short Interest
Short Ratio3.0d
Short % Float1.37%
Short % Out.1.35%
Shares Short110.96K
Short (prev mo.)141.72K
Technical
SMA 502.245 (-6.9%)
SMA 2004.532 (-53.9%)
Beta0.46
S&P 52W Chg18.16%
Avg Vol (30d)35.91K
Avg Vol (10d)31.22K
Technical Indicators
RSI (14)43.5
MACD-0.0539
MACD Signal-0.0585
MACD Hist.+0.0046
BB Upper2.184 USD
BB Middle2.107 USD
BB Lower2.029 USD
BB Width7.35%
ATR (14)0.1119 USD
Vol Ratio (20d)0.43x